...
首页> 外文期刊>BMC Infectious Diseases >Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany
【24h】

Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany

机译:德国成人和儿童抵抗小儿麻痹症病毒1型CHAT和Sabin(LSc-2ab)的免疫状况

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background In October 2007, the working group CEN/TC 216 of the European Committee for standardisation suggested that the Sabin oral poliovirus vaccine type 1 strain (LSc-2ab) presently used for virucidal tests should be replaced by another attenuated vaccine poliovirus type 1 strain, CHAT. Both strains were historically used as oral vaccines, but the Sabin type 1 strain was acknowledged to be more attenuated. In Germany, vaccination against poliomyelitis was introduced in 1962 using the oral polio vaccine (OPV) containing Sabin strain LSc-2ab. The vaccination schedule was changed from OPV to an inactivated polio vaccine (IPV) containing wild polio virus type 1 strain Mahoney in 1998. In the present study, we assessed potential differences in neutralising antibody titres to Sabin and CHAT in persons with a history of either OPV, IPV, or OPV with IPV booster. Methods Neutralisation poliovirus antibodies against CHAT and Sabin 1 were measured in sera of 41 adults vaccinated with OPV. Additionally, sera from 28 children less than 10 years of age and immunised with IPV only were analysed. The neutralisation assay against poliovirus was performed according to WHO guidelines. Results The neutralisation activity against CHAT in adults with OPV vaccination history was significantly lower than against Sabin poliovirus type 1 strains (Wilcoxon signed-rank test P Conclusion The lack of neutralising antibodies against the CHAT strain in persons vaccinated with OPV might be associated with an increased risk of reinfection with the CHAT polio virus type 1, and this implies a putative risk of transmission of the virus to polio-free communities. We strongly suggest that laboratory workers who were immunised with OPV receive a booster vaccination with IPV before handling CHAT in the laboratory.
机译:背景技术2007年10月,欧洲标准化委员会CEN / TC 216工作组建议,目前用于杀伤性试验的萨宾口腔脊髓灰质炎病毒1型病毒株(LSc-2ab)应替换为另一株减毒的脊髓灰质炎病毒1型疫苗,聊天。历史上,这两种菌株都用作口服疫苗,但公认Sabin 1型菌株减毒性更高。在德国,1962年使用含Sabin菌株LSc-2ab的口服脊髓灰质炎疫苗(OPV)引入了针对小儿麻痹症的疫苗。在1998年,疫苗接种时间表从OPV改为包含脊髓灰质炎1型野生脊髓灰质炎病毒的灭活脊髓灰质炎疫苗(IPV)。在本研究中,我们评估了既往有既往史或既往史的人中和Sabin和CHAT抗体滴度的潜在差异OPV,IPV或带IPV增强器的OPV。方法在41例接种OPV的成人血清中测定抗CHAT和Sabin 1的中和脊髓灰质炎病毒抗体。此外,分析了28名10岁以下儿童的血清,仅用IPV免疫。根据世界卫生组织指南进行了针对脊髓灰质炎病毒的中和测定。结果接受过OPV疫苗接种的成年人对CHAT的中和活性明显低于对Sabin脊髓灰质炎病毒1型菌株的抗中和活性(Wilcoxon秩和检验P结论接种OPV的人缺乏针对CHAT菌株的中和抗体可能与抗病毒能力增强有关再次感染1型CHAT脊髓灰质炎病毒的风险,这意味着该病毒可能会传播到无脊髓灰质炎的社区中,我们强烈建议接受OPV免疫的实验室工作人员应在IPA中处理CHAT疫苗之前接受IPV加强疫苗接种。实验室。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号